IL17A and Alzheimer disease: Prior to the diagnosis of AD, systemic treatments received by psoriatic patients included methotrexate in 4.2% (n = 1/24), an anti-IL-17 agent in 33.3% (n = 8/24), and an anti-IL-23 agent in 41.7% (n = 10/24).